Rein Therapeutics Inc (NASDAQ:RNTX) — Market Cap & Net Worth
Market Cap & Net Worth: Rein Therapeutics Inc (RNTX)
Rein Therapeutics Inc (NASDAQ:RNTX) has a market capitalization of $63.04 Million ($63.04 Million) as of August 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #20921 globally and #4652 in its home market, demonstrating a -7.89% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Rein Therapeutics Inc's stock price $0.74 by its total outstanding shares 85539032 (85.54 Million). Review how much debt does Rein Therapeutics Inc carry to assess the company's total debt and financial obligations.
Rein Therapeutics Inc Market Cap History: 2025 to 2026
Rein Therapeutics Inc's market capitalization history from 2025 to 2026. Data shows change from $99.23 Million to $63.04 Million (-47.48% CAGR).
Index Memberships
Rein Therapeutics Inc is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.46 Trillion | 0.00% | #596 of 976 |
Weight: Rein Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Rein Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Rein Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of RNTX by Market Capitalization
Companies near Rein Therapeutics Inc in the global market cap rankings as of August 3, 2026.
Key companies related to Rein Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
Rein Therapeutics Inc Historical Marketcap From 2025 to 2026
Between 2025 and today, Rein Therapeutics Inc's market cap moved from $99.23 Million to $ 63.04 Million, with a yearly change of -47.48%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $63.04 Million | -36.47% |
| 2025 | $99.23 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 3rd, 2026 the market cap of Rein Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $63.04 Million USD |
| MoneyControl | $63.04 Million USD |
| MarketWatch | $63.04 Million USD |
| marketcap.company | $63.04 Million USD |
| Reuters | $63.04 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Rein Therapeutics Inc
Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). It also offers LTI-01, a proenzyme that has completed Phase 1b a… Read more